End-of-day quote
Other stock markets
|
||
- LVL | - |
Apr. 03 | Grindeks Opens New Subsidiaries Worldwide | CI |
2021 | JSC Grindeks Appoints Andrejs Liberts as the Member of the Board | CI |
Business Summary
- research, development and manufacturing of pharmaceuticals (94.9%): medicines for the treatment of cardiovascular diseases, cancers and central nervous system disorders, analgesic products, treatments of cough and flu, etc.;
- production of pharmaceutical active ingredients (5.1%).
Net sales break down geographically as follows: Latvia (6.6%), Russia (59.6%), Lithuania (4%), Estonia (1.7%) and other (28.1%).
Managers
Managers | Title | Age | Since |
---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 44 | - |
Director of Finance/CFO | 64 | 02-12-31 | |
Dmitry Saikovky
CTO | Chief Tech/Sci/R&D Officer | - | - |
Eric Ivanovsky
CTO | Chief Tech/Sci/R&D Officer | - | - |
Andrejs Liberts
PRN | Corporate Officer/Principal | 39 | 21-02-23 |
Iveta Zomerfelde
SAM | Sales & Marketing | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kirovs Lipmans
CHM | Chairman | 83 | 02-12-31 |
Anna Lipmane
BRD | Director/Board Member | 76 | 07-12-31 |
Filips Lipmans
BRD | Director/Board Member | 46 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 9,585,000 | 308,478 ( 3.218 %) | 0 | 3.218 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+34.85% | 24.51B | |
+29.56% | 16.85B | |
+22.37% | 14.62B | |
+73.62% | 14.16B | |
-0.05% | 6.79B | |
-10.06% | 6.73B | |
+15.74% | 5.82B | |
-8.87% | 5.73B | |
+10.74% | 4.93B |
- Stock Market
- Equities
- GRD1R Stock
- GRD1R Stock
- Company Grindeks AS